triazoles has been researched along with Low Bone Density in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hegazy, SK | 1 |
| Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N | 1 |
| Vestergaard, P | 1 |
| Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P | 1 |
| Gibson, K; O'Bryant, CL | 1 |
| Geisler, J; Lønning, PE | 1 |
| Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA | 1 |
| Markopoulos, C | 1 |
| Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Denes, AE | 1 |
1 review(s) available for triazoles and Low Bone Density
| Article | Year |
|---|---|
Skeletal effects of drugs to treat cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Diseases, Metabolic; Fractures, Bone; Humans; Neoplasms; Nitriles; Triazoles | 2008 |
3 trial(s) available for triazoles and Low Bone Density
| Article | Year |
|---|---|
Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Lumbar Vertebrae; Metformin; Middle Aged; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Postmenopause; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2008 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Risk Factors; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
6 other study(ies) available for triazoles and Low Bone Density
| Article | Year |
|---|---|
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis; Triazoles; Zoledronic Acid | 2016 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteoporosis; Retrospective Studies; Triazoles | 2008 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Letrozole; Nitriles; Triazoles; Vitamin D | 2010 |
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Topics: Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Nitriles; Osteoporosis; Triazoles | 2010 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Outcome and Process Assessment, Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Time Factors; Triazoles | 2012 |
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2005 |